Litcius/Paper detail

Tremella fuciformis polysaccharides induce ferroptosis in Epstein–Barr virus-associated gastric cancer by inactivating NRF2/HO-1 signaling

Wencheng Kong, Xinchun Liu, Hangzhang Zhu, Sixing Zheng, Guang Yin, Panpan Yu, Yuqiang Shan, Shenglin Ma, Rongchao Ying, Huicheng Jin

2024Aging13 citationsDOIOpen Access PDF

Abstract

polysaccharides (TFPs) are characterized by antioxidative and anti-inflammatory effects in different diseases. However, whether TFP improves EBV-associated gastric cancer (EBVaGC) has never been explored. The effects of TFP on EBV-infected GC cell viability were determined using a CCK-8 assay and flow cytometry. Western blotting and RT-qPCR were performed to explore the expression of ferroptosis-related proteins. The CCK-8 assay showed that TFP decreased EBV-infected GC cell viability in a dose- and time-dependent manner. Flow cytometry assays indicated that TFP significantly induced EBV-infected GC cell death. TFP also reduced the migratory capacity of EBV-infected GC cells. Furthermore, treatment with TFP significantly increased the mRNA levels of PTGS2 and Chac1 in EBV-infected GC cells. Western blot assays indicated that TFP suppressed the expression of NRF2, HO-1, GPX4 and xCT in EBV-infected GC cells. More importantly, overexpression of NRF2 could obviously rescue TFP-induced downregulation of GPX4 and xCT in EBV-infected GC cells. In summary, we showed novel data that TFP induced ferroptosis in EBV-infected GC cells by inhibiting NRF2/HO-1 signaling. The current findings may shed light on the potential clinical application of TFP in the treatment of EBVaGC.

Topics & Concepts

Flow cytometryEpstein–Barr virusViability assayWestern blotBlotBiologyApoptosisCancer researchDownregulation and upregulationMolecular biologyVirusImmunologyBiochemistryGeneCancer-related molecular mechanisms researchFerroptosis and cancer prognosisCholangiocarcinoma and Gallbladder Cancer Studies
Tremella fuciformis polysaccharides induce ferroptosis in Epstein–Barr virus-associated gastric cancer by inactivating NRF2/HO-1 signaling | Litcius